ConductScience.org, home

Paper856462

Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function.

Benjamin RS and 2 others. Cancer Res, 1977. Cited by 243 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Papers, record 856462. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/856462

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function.
PubMed
Journal
Cancer Res
PubMed
Year
1977
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
243
iCite
Relative citation ratio, by iCite
10.3
iCite
Revised in PubMed
2022-03-21
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Benjamin RSR S
2Riggs CE JrC E
3Bachur NRN R

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
DoxorubicinMajor topic
Half-Life
Humans
Kidney
Liver
Neoplasms

Cited by65

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 243 citations.

PMIDTitleJournalYearIn PapersSource
38609583Combination of Doxorubicin and Antiangiogenic Agents in Drug-Eluting Beads: In Vitro Loading and Release Dynamics in View of a Novel Therapeutic Approach for Hepatocellular Carcinoma.Cardiovasc Intervent Radiol2024https://conductscience.org/library/papers/38609583PubMed
33404976Multiscale and Translational Quantitative Systems Toxicology, Pharmacokinetic-Toxicodynamic Modeling Analysis for Assessment of Doxorubicin-Induced Cardiotoxicity.AAPS J2021https://conductscience.org/library/papers/33404976PubMed
30221011Randomized study of doxorubicin-based chemotherapy regimens, with and without sildenafil, with analysis of intermediate cardiac markers.Cardiooncology2018https://conductscience.org/library/papers/30221011PubMed
27007464Nodal expression in triple-negative breast cancer: Cellular effects of its inhibition following doxorubicin treatment.Cell Cycle2016https://conductscience.org/library/papers/27007464PubMed
25909710Plasma TNF-α and Soluble TNF Receptor Levels after Doxorubicin with or without Co-Administration of Mesna-A Randomized, Cross-Over Clinical Study.PLoS One2015https://conductscience.org/library/papers/25909710PubMed
22964943A mechanistic study of the effect of doxorubicin/adriamycin on the estrogen response in a breast cancer model.Oncology2012https://conductscience.org/library/papers/22964943PubMed
20653682Failure of liver function tests in predicting drug clearance of chemotherapeutic agents in a patient who had recovered from hepatic congestion.Br J Clin Pharmacol2010https://conductscience.org/library/papers/20653682PubMed
18749444Cardiotoxic effects of anthracyclines.West J Med1983https://conductscience.org/library/papers/18749444PubMed
15656694Interactions between antiretrovirals and antineoplastic drug therapy.Clin Pharmacokinet2005https://conductscience.org/library/papers/15656694PubMed
8738403Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder.World J Urol1996https://conductscience.org/library/papers/8738403PubMed
8453681Prochlorperazine as a doxorubicin-efflux blocker: phase I clinical and pharmacokinetics studies.Cancer Chemother Pharmacol1993https://conductscience.org/library/papers/8453681PubMed
8269583Effects of the methoxymorpholino derivative of doxorubicin and its bioactivated form versus doxorubicin on human leukemia and lymphoma cell lines and normal bone marrow.Cancer Chemother Pharmacol1993https://conductscience.org/library/papers/8269583PubMed
8137454Pharmacokinetics of doxorubicin and its active metabolite in patients with normal renal function and in patients on hemodialysis.Cancer Chemother Pharmacol1994https://conductscience.org/library/papers/8137454PubMed
7599068An evaluation of hepatic extraction and clearance of doxorubicin.Br J Cancer1995https://conductscience.org/library/papers/7599068PubMed
7397946Influence of tumor on adriamycin concentration in blood cells.Cancer Chemother Pharmacol1980https://conductscience.org/library/papers/7397946PubMed
7350193Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin.J Clin Invest1980https://conductscience.org/library/papers/7350193PubMed
7287901Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine.J Clin Invest1981https://conductscience.org/library/papers/7287901PubMed
7274305Differential adriamycin distribution to blood components.Eur J Drug Metab Pharmacokinet1981https://conductscience.org/library/papers/7274305PubMed
7206588[The pharmacokinetics of adriamycin and adriamycin-metabolites (author's transl)].Klin Wochenschr1980https://conductscience.org/library/papers/7206588PubMed
7059411Dosage adjustment in renal insufficiency.Br J Clin Pharmacol1982https://conductscience.org/library/papers/7059411PubMed

See all 65 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/856462

GET https://conductscience.org/api/papers/v1/856462/cited_by?page=2